Latest revenue
$25.6M
as of 2026-03-31
Latest net income
$-7.8M
as of 2026-03-31
Net margin
-30.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $150.9M
- Enterprise value
- $150.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $20.21
- 52-wk low
- $0.25
- Beta
- —
- Shares out
- 10.1M
5-year trend
What this company does
Item 1. Business. Business Overview Biodesix, Inc. (“Biodesix”, “we,” “us,” “our” or the “Company”) is a leading diagnostic solutions company. Our mission at Biodesix is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs. We envision a world where patient disease is conquered through the guidance of personalized diagnostics. We derive our revenue from two sources: (i) Biodesix Lung Diagnostic Testing (Lung Diagnostic Testing), providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Biodesix Development Services (Development Services)…
AI summary unavailable — showing raw filing excerpt
Generated from BDSX's filing dated 2026-02-26
Key risks
Factors. Risk Factors Summary The following is a summary of the principal risks that could adversely affect our business, operations and financial results. This summary does not address all of the risk that we face and should be read in conjunction with the entire Risk Factors section below beginning at “Risks Related to Our Business and Industry” within this Item 1A. "Risk Factors." •We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it; •The commercial success of our current and future diagnostic tests and services and our revenue growth depends upon attaining significant market…
AI summary unavailable — showing raw filing excerpt
Generated from BDSX's filing dated 2026-02-26
Profitability
Operating margin
-31.5%
34.9%Net margin
-39.8%
33.8%Return on equity
1430.6%
795.7%Return on assets
-40.3%
8.7%Leverage
Debt / equity
-36.49×
1097.4%Long-term debt / equity
-19.25×
1203.6%Debt / assets
102.8%
30.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $25.6M | +42.3% | $-7.8M | +29.8% | -30.5% |
Q4 2025 2025-12-31 | $28.8M | +40.8% | $-4.0M | +51.8% | -13.8% |
Q3 2025 2025-09-30 | $21.8M | +19.9% | $-8.7M | +15.0% | -40.0% |
Q2 2025 2025-06-30 | $20.0M | +11.7% | $-11.5M | -6.1% | -57.3% |
Q1 2025 2025-03-31 | $18.0M | +21.2% | $-11.1M | +18.5% | -61.8% |
Q4 2024 2024-12-31 | $20.4M | — | $-8.3M | — | -40.4% |
Q3 2024 2024-09-30 | $18.2M | +34.5% | $-10.3M | +6.3% | -56.5% |
Q2 2024 2024-06-30 | $17.9M | +51.0% | $-10.8M | +19.1% | -60.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on BDSX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$4.7M
Insider selling
$120.8K
Net activity
+$4.6M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns BDSX
Institutional value
$34.4M
Total shares held
2.4M
Distinct holders
21
-3 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 758.3K | $11.0M | — | New |
| 2 | Telemark Asset Management, LLC | 489.8K | $7.1M | +162.0K (+49.4%) | Added |
| 3 | abrdn plc | 458.4K | $6.6M | +196.0K (+74.7%) | Added |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 255.2K | $3.7M | — | New |
| 5 | ESSEX INVESTMENT MANAGEMENT CO LLC | 132.1K | $1.9M | — | New |
| 6 | PERKINS CAPITAL MANAGEMENT INC | 44.8K | $649.4K | +0 (+0.0%) | No change |
| 7 | SEI INVESTMENTS CO | 43.0K | $623.8K | — | New |
| 8 | UBS Group AG | 36.8K | $533.7K | — | New |
| 9 | VANGUARD FIDUCIARY TRUST CO | 28.7K | $415.6K | — | New |
| 10 | BLAIR WILLIAM & CO/IL | 27.6K | $400.0K | — | New |
| 11 | JANE STREET GROUP, LLC | 27.0K | $391.9K | — | New |
| 12 | BlackRock, Inc. | 24.5K | $354.8K | +0 (+0.0%) | No change |
| 13 | Walleye Capital LLC | 21.7K | $314.4K | — | New |
| 14 | Cetera Investment Advisers | 12.0K | $174.0K | +2.0K (+20.0%) | Added |
| 15 | THOMPSON DAVIS & CO., INC. | 11.8K | $170.4K | — | New |
| 16 | Vanguard Global Advisers, LLC | 1.1K | $15.3K | — | New |
| 17 | BNP PARIBAS FINANCIAL MARKETS | 924 | $13.4K | — | New |
| 18 | Fortitude Family Office, LLC | 171 | $2.5K | +0 (+0.0%) | No change |
| 19 | GROUP ONE TRADING LLC | 100 | $1.4K | +0 (+0.0%) | No change |
| 20 | GSA CAPITAL PARTNERS LLP | 39.4K | $571 | -25.1K (-38.9%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BDSX's latest filing finishes processing.